Bis(hetero)aryl derivatives as unique kinesin spindle protein inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 4, 2009, Pages 1058-1061

  Matsuno, Kenji ^a   Sawada, Jun ichi ^a   Sugimoto, Mina ^a   Ogo, Naohisa ^a   Asai, Akira ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Anticancer; Inhibitor; KSP; Mitotic kinesin

Indexed keywords

4 (4 TERT BUTYLPHENYL)PYRIDINE; ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; ARRY 520; EMD 534085; GSK 1; ISPINESIB; KINESIN; KINESIN SPINDLE PROTEIN; KINESIN SPINDLE PROTEIN INHIBITOR; MK 0731; MONASTROL; PVZB 1084; PVZB 1194; SB 743921; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL MODIFICATION; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; HELA CELL; HUMAN; HUMAN CELL; MICROTUBULE; MITOSIS; MITOSIS SPINDLE; PROTEIN LOCALIZATION; STRUCTURE ACTIVITY RELATION; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

COMBINATORIAL CHEMISTRY TECHNIQUES; HELA CELLS; HUMANS; KINESIN; MITOSIS; MITOTIC SPINDLE APPARATUS; MOLECULAR STRUCTURE; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 59649119154     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.01.018     Document Type: Article

References (23)

1. Miki H., Okada Y., and Hirokawa N. Trends Cell Biol. 15 (2005) 467
2. Sawin K.E., Leguellec K., Philippe M., and Mitchison T.J. Nature 359 (1992) 540
3. Blangy A., Lane H.A., D'Herin P., Harper M., Kress M., and Niggt E.A. Cell 83 (1995) 1159
4. Tao W., South V.J., Zhang Y., Davide J.P., Farrell L., Kohl N.E., Sepp-Lorenzino L., and Lobell R.B. Cancer Cell 8 (2005) 49
5. Weaver B.A., and Cleveland D.W. Cancer Cell 8 (2005) 7
6. Tao W., South V.J., Diehl R.E., Davide J.P., Sepp-Lorenzino L., Fraley M.E., Arrington K.L., and Lobell R.B. Mol. Cell Biol. 27 (2007) 689
7. Kapoor T.M., Mayer T.U., Coughlin M.L., and Mitchison T.J. J. Cell Biol. 150 (2000) 975
8. Sharp D.J., Rogers G.C., and Scholey J.M. Nature 407 (2000) 41
9. Mayer T.U., Kapoor T.M., Haggarty S.J., King R.W., Schreiber S.L., and Mitchison T.J. Science 286 (1999) 971
10. Ogo N., Oishi S., Matsuno K., Sawada J.-i., Fujii N., and Asai A. Bioorg. Med. Chem. Lett. 17 (2007) 3921
11. Luo L., Carson J.D., Molnar K.S., Tuske S.J., Coales S.J., Hamuro Y., Sung C.-m., Sudakin V., Auger K.R., Dhanak D., Jackson J.R., Huang P.S., Tummino P.J., and Copeland R.A. J. Am. Chem. Soc. 130 (2008) 7584
12. Bergnes G., Brejc K., and Belmont L. Curr. Top. Med. Chem. 5 (2005) 127
13. Duhl D.M., and Renhowe P.A. Curr. Opin. Drug Discov. Dev. 8 (2005) 431
14. Matsuno K., Sawada J.-i., and Asai A. Expert Opin. Ther. Patents 18 (2008) 253
15. Blagden S.P., Molife L.R., Seebaran A., Payne M., Reid A.H., Protheroe A.S., Vasist L.S., Williams D.D., Bowen C., Kathman S.J., Hodge J.P., Dar M.M., de Bono J.S., and Middleton M.R. Br. J. Cancer 98 (2008) 894
16. Holen, K. D.; Belani, C. P.; Wilding, G.; Ramalingam, S.; Heideman, J. L.; Ramanathan, R. K.; Bowen, C, J.; Williams, D. D.; Hodge, J. P.; Dar, M. M. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I 2006, 24, Abst. 2000.
17. Cox C.D., Coleman P.J., Breslin M.J., Whitman D.B., Garbaccio R.M., Fraley M.E., Buser C.A., Walsh E.S., Hamilton K., Schaber M.D., Lobell R.B., Tao W., Davide J.P., Diehl R.E., Abrams M.T., South V.J., Huber H.E., Torrent M., Prueksaritanont T., Li C., Slaughter D.E., Mahan E., Fernandez-Metzler C., Yan Y., Kuo L.C., Kohl N.E., and Hartman G.D. J. Med. Chem. 51 (2008) 4239
18. See http://www.clinicaltrials.gov.
19. Finsinger, D.; Zenke, F. T.; Amendt, C.; Schiemann, K.; Emde, U.; Knöchel, T.; Bomke, J.; Gleitz, J.; Wilm, C.; Meyring, M.; Osswald, M.; Funk, J.-O. Proc. Am. Assoc. Cancer Res. (AACR) 2006, 47, Abst. 5713.
20. Parrish C.A., Adams N.D., Auger K.R., Burgess J.L., Carson J.D., Chaudhari A.M., Copeland R.A., Diamond M.A., Donatelli C.A., Duffy K.J., Faucette L.F., Finer J.T., Huffman W.F., Hugger E.D., Jackson J.R., Knight S.D., Luo L., Moore M.L., Newlander K.A., Ridgers L.H., Sakowicz R., Shaw A.N., Sung C.-M.M., Sutton D., Wood K.W., Zhang S.-Y., Zimmerman M.N., and Dhanak D. J. Med. Chem. 50 (2007) 4939
21. Brier S., Lemaire D., DeBonis S., Forest E., and Kozielski F. J. Mol. Biol. 360 (2006) 360
22. Luo L., Parrish C.A., Nevins N., McNulty D.E., Chaudhari A.M., Carson J.D., Sudakin V., Shaw A.N., Lehr R., Zhao H., Sweitzer S., Lad L., Wood K.W., Sakowicz R., Annan R.S., Huang P.S., Jackson J.R., Dhanak D., Copeland R.A., and Auger K.R. Nat. Chem. Biol. 3 (2007) 722
23. HeLa cells treated with KSP inhibitors were fixed by the conventional paraformaldehyde/methanol method, and stained immunologically. DNA/chromatin, microtubules, mitotic chromatin and KSP were stained by DAPI, monoclonal anti-α-tubulin (DM1A) antibody (Sigma), anti-phospho-Histon H3 (Ser10) antibody (Upstate) and anti-KSP antibody (Cytoskeleton), respectively. Fluorescent images were observed under an Olympus IX71 microscope with a DP30BW CCD camera.